The ODYSSEY OUTCOMES trial involved 18,924 post-ACS patients, ~90% of whom were taking high-intensity statins:1†
Designed to evaluate the long-term efficacy and safety of Praluent® in post-ACS patients3
Adapted from Schwartz et al. 2018 and Schwartz et al.1,4
¥Background therapy: 96% aspirin, 88% P2Y12 inhibitor, 85% beta blocker, 78% ACE/ARBs.5
§Dose was up-titrated from 75 mg Q2W to 150 mg Q2W at month 2 if LDL-C was ≥50 mg/dL at month 1. Dose was down-titrated from 150 mg Q2W to 75 mg Q2W if LDL-C was <25 mg/dL on 2 consecutive measures. Patients on the 75 mg Q2W dose were blindly switched to placebo if LDL-C was <15 mg/dL on 2 consecutive measures.
Primary endpoint (time to first occurrence of)3
Major secondary endpoints (in order of hierarchical testing)3¶
Other secondary endpoints1